DK1981862T3 - Lanthioninbeslægtede forbindelser til behandling af inflammatoriske sygdomme - Google Patents
Lanthioninbeslægtede forbindelser til behandling af inflammatoriske sygdommeInfo
- Publication number
- DK1981862T3 DK1981862T3 DK07710015.4T DK07710015T DK1981862T3 DK 1981862 T3 DK1981862 T3 DK 1981862T3 DK 07710015 T DK07710015 T DK 07710015T DK 1981862 T3 DK1981862 T3 DK 1981862T3
- Authority
- DK
- Denmark
- Prior art keywords
- lanthionine
- compounds
- derivatives
- treatment
- provides
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 title abstract 2
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title 1
- XIVVIYYWXOMYOD-UHFFFAOYSA-N lanthionine ketimine Chemical class OC(=O)C1CSCC(C(O)=O)=N1 XIVVIYYWXOMYOD-UHFFFAOYSA-N 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- GDTAKZOTFKBAGC-UHFFFAOYSA-N thiomorpholine-3,4-dicarboxylic acid Chemical class OC(=O)C1CSCCN1C(O)=O GDTAKZOTFKBAGC-UHFFFAOYSA-N 0.000 abstract 2
- 230000003215 anti-neuroinflammatory effect Effects 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75725206P | 2006-01-09 | 2006-01-09 | |
| US78179406P | 2006-03-13 | 2006-03-13 | |
| US80414906P | 2006-06-07 | 2006-06-07 | |
| PCT/US2007/060277 WO2007082208A2 (en) | 2006-01-09 | 2007-01-09 | Lanthionine-related compounds for the treatment of inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1981862T3 true DK1981862T3 (da) | 2011-06-14 |
Family
ID=38051848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07710015.4T DK1981862T3 (da) | 2006-01-09 | 2007-01-09 | Lanthioninbeslægtede forbindelser til behandling af inflammatoriske sygdomme |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7683055B2 (enExample) |
| EP (1) | EP1981862B1 (enExample) |
| JP (1) | JP5367377B2 (enExample) |
| AT (1) | ATE500236T1 (enExample) |
| AU (1) | AU2007204757B2 (enExample) |
| CA (1) | CA2636042C (enExample) |
| DE (1) | DE602007012833D1 (enExample) |
| DK (1) | DK1981862T3 (enExample) |
| PT (1) | PT1981862E (enExample) |
| WO (1) | WO2007082208A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305834A1 (en) * | 2009-10-02 | 2011-04-06 | Advanced Practical Diagnostics N.V. | Haplotype of KATIII gene |
| RU2518890C2 (ru) * | 2009-12-28 | 2014-06-10 | Адзиномото Ко., Инк. | Производные лантионина |
| US9101573B2 (en) | 2010-05-04 | 2015-08-11 | Virginia Tech Intellectual Properties, Inc. | Lanthionine synthetase component C-like proteins as molecular targets for preventing and treating diseases and disorders |
| US20130209366A1 (en) * | 2010-08-24 | 2013-08-15 | Oklahoma Medical Research Foundation | Glutathione-Lanthionine Compounds and Methods Related Thereto |
| CN102670796A (zh) * | 2012-05-22 | 2012-09-19 | 广西天天乐药业股份有限公司 | 一种治疗脾胃虚弱的中药及其制备方法 |
| JP2017141497A (ja) * | 2016-02-12 | 2017-08-17 | 二村 芳弘 | エラスチン増加作用を呈するメチルランチオニン誘導体の製造方法 |
| US11084836B2 (en) * | 2016-02-26 | 2021-08-10 | The University Of Toledo | Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same |
| WO2018156429A1 (en) * | 2017-02-23 | 2018-08-30 | The University Of Toledo | Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2283186A (en) * | 1942-05-19 | Thiazane-j | ||
| US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| AU2002247939B2 (en) * | 2001-01-16 | 2007-01-25 | Serono Genetics Institute S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| US20030185754A1 (en) | 2001-01-16 | 2003-10-02 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| US20030166554A1 (en) * | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
-
2007
- 2007-01-09 DK DK07710015.4T patent/DK1981862T3/da active
- 2007-01-09 JP JP2008549685A patent/JP5367377B2/ja not_active Expired - Fee Related
- 2007-01-09 CA CA2636042A patent/CA2636042C/en not_active Expired - Fee Related
- 2007-01-09 AU AU2007204757A patent/AU2007204757B2/en not_active Ceased
- 2007-01-09 PT PT07710015T patent/PT1981862E/pt unknown
- 2007-01-09 EP EP07710015A patent/EP1981862B1/en not_active Not-in-force
- 2007-01-09 WO PCT/US2007/060277 patent/WO2007082208A2/en not_active Ceased
- 2007-01-09 AT AT07710015T patent/ATE500236T1/de active
- 2007-01-09 DE DE602007012833T patent/DE602007012833D1/de active Active
- 2007-01-09 US US11/621,469 patent/US7683055B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7683055B2 (en) | 2010-03-23 |
| ATE500236T1 (de) | 2011-03-15 |
| US20070197515A1 (en) | 2007-08-23 |
| WO2007082208A2 (en) | 2007-07-19 |
| EP1981862B1 (en) | 2011-03-02 |
| AU2007204757A1 (en) | 2007-07-19 |
| PT1981862E (pt) | 2011-06-01 |
| DE602007012833D1 (de) | 2011-04-14 |
| JP2009522377A (ja) | 2009-06-11 |
| CA2636042C (en) | 2014-10-14 |
| JP5367377B2 (ja) | 2013-12-11 |
| EP1981862A2 (en) | 2008-10-22 |
| AU2007204757B2 (en) | 2012-09-06 |
| WO2007082208A3 (en) | 2007-09-13 |
| CA2636042A1 (en) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA95644C2 (ru) | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний | |
| DK1981862T3 (da) | Lanthioninbeslægtede forbindelser til behandling af inflammatoriske sygdomme | |
| DE602007012133D1 (de) | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten | |
| WO2010044981A3 (en) | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | |
| MY153915A (en) | Organic compounds | |
| NO20090596L (no) | Antivirale fosfinatforbindelser | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201170772A1 (ru) | Органические соединения | |
| MX2012002542A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina. | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| CL2012001971A1 (es) | Compuestos derivados de 1-piperazinil-3-piridin-carboxilato, como bloqueadores de los canales de sodio dependientes de voltaje; composicion farmaceutica; y su uso para el tratamiento de enfermedades respiratorias o del tracto respiratorio tal como asma, epoc, tos, silicosis, entre otras. | |
| GEP20135964B (en) | Inhibitors of beta-secretase | |
| BR112014021531A8 (pt) | composto, composição farmacêutica e usos dos mesmos | |
| EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
| WO2008061724A3 (en) | Compositions comprising carnosic acid 12-methylether | |
| UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| WO2011132051A3 (en) | Tricycle compounds as phosphodiesterase-10 inhibitors | |
| MX2009010174A (es) | Derivados de aza-adamantano ester y carbamato y metodos de uso de los mismos. | |
| MA32406B1 (fr) | Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens | |
| CL2009000510A1 (es) | Compuestos derivados de 1,3,5,6,7,8-hexahidro-furo[3,4-b]quinolina, inhibidores de cetp; proceso de preparacion de los compuestos; composicion farmaceutica; proceso de preparacion de la composicion; y uso en el tratamiento y/o prevencion de trastornos cardiovasculares y trastornos relacionados. | |
| TW200745122A (en) | New compounds I | |
| WO2014064652A3 (en) | Stable pharmaceutical composition of peginterferon alpha-2b | |
| WO2007066337A3 (en) | Jasmonate derivatives, pharmaceutical compositions and methods of use thereof | |
| WO2008033935A3 (en) | Vinorelbine derivatives |